Tailoring the management of hypertension to comorbidities.
Curr Opin Cardiol
; 36(4): 405-412, 2021 07 01.
Article
in English
| MEDLINE | ID: covidwho-1301390
ABSTRACT
PURPOSE OF REVIEW In this article, we review the most current evidence for initiation and maintenance of various antihypertension (HTN) drug classes, including other misconceptions with respect to common comorbidities in patients with HTN. RECENT FINDINGS:
Although the currently available anti-HTN agents have broad applicability in treating HTN, additional agents, such as angiotensin receptor-neprilysin inhibitors and novel nonsteroidal mineralocorticoid antagonists, have recently gained clinical significance. In addition, there have been some anecdotal concerns regarding the adverse effects, indications, and risks of COVID-19 infection/mortality when using certain anti-HTN agents.SUMMARY:
Current guidelines currently address the treatment of primary HTN. However, isolated HTN is uncommon and often involves comorbid diseases that require specific regimentation. Several experimental medications are currently in late-stage trials showing potential superiority over current drugs that are available in the market.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Hypertension
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Curr Opin Cardiol
Journal subject:
Cardiology
Year:
2021
Document Type:
Article
Affiliation country:
HCO.0000000000000860
Similar
MEDLINE
...
LILACS
LIS